However, when examining global methylation patterns, the pediatric population displayed a significantly hypermethylated genome compared with the adult population (Figure 5F; P < 0.0001), suggesting that hypermethylation at cluster 1 CpG sites is a distinctive characteristic of pediatric CNS cancers, potentially benefiting from MCL1 inhibitor therapy. This evidence concerns the gene MCL1 and central nervous system cancer.